Zoladex implant

Dosage Goserelin (GnRH Analog, Zoladex) Implants... 

Zoladex implants are indicated for use in the palliative treatment of advanced breast cancer in pre- and peri-menopausal women, in the palliative treatment of advanced carcinoma of the prostate and in the management of endometriosis, including pain relief and the reduction of endometriotic lesions. The implant is fabricated by dispersing goserelin in a PLGA matrix and molding it into a cylindrical shape, which can be injected subcutaneously. 

The release profile of goserelin from the implants has been well characterized during product development. For example, in a study of a Zoladex implant loaded with 10.8 mg of drug, the goserelin present at the surface of the implant was released rapidly, so that mean concentrations increased and reached peak levels within the first 24 hours. The initial release was then followed by a lag period up to 4 days, in which there was a rapid decline in the plasma concentration of the drug. 

The discontinuous two phases drug release can be controlled and avoided by manipulating the degradation properties of the polymer so that it is possible for the Zoladex implant to provide continuous release over a 28-day period. 

Fig. 43 SEM picture of a Zoladex cylindrical implant. The stripes at the lower surface result from small irregularities of the extrusion nozzle (A). One end of a Zoladex implant at a higher magnification. The cross-sectional area shows irregularities resulting from the cut off of single cylinders (B).

Goserelin (Zoladex), a hormonal antineoplastic drug used to treat breast cancer, is administered subcutaneously in an unusual way. The drag is contained in a dry pellet that is implanted in the soft tissue of the abdomen, where it is gradually absorbed during a period of 1 to 3 months. After a local anesthetic, such as lido-caine, is administered, a large needle (usually 16 gauge) is used to insert the pellet. 

Dosage forms Zoladex is supplied as a sterile, biodegradable implant containing goserelin acetate equivalent to 3.6mg of... 

Route of administration Zoladex is injected as a subcutaneous implant. The injection site of choice is the upper abdominal wall, but the midline of the lower abdomen has also been used. 

Which of the following is/are an example(s) of non-biodegradable matrix-type implant (a) Norplant (b) Compudose (c) Implanon and/or (d) Zoladex. 

In contrast to these microsphere formulations, Zoladex (AstraZeneca) is a small implantable cylinder (approximately 1mm in diameter and 10 mm in length) containing goserelin acetate in a polymer matrix of 50 50 PLG. This system delivers approximately 3.6 mg drug over a 1-month period and is indicated for the treatment of prostate cancer. A second Zoladex system containing 10.6 mg goserelin has also been developed to release the drug for over 3 months. ... 

Zoladex is DL-poly-lactide-glycolide. The implants are cylindrical in shape and have a diameter enabling the application by syringes and injection needles. A scheme of the preparation of this type of implants is... 

Zoladex (gosorelin acetate implant) biodegradable polymeric particles capable of continuously delivering gosorelin for 3 months as a palliative treatment for advanced prostate cancer. 

The Norplant device has been somewhat controversial, however, due to difficulties associated with its removal. A second example of an implantable drug delivery system is Zoladex, which is an implantable biodegradable lactide/glycolide polymeric delivery system for the administration of goserelin acetate. It is available in one-month and three-month presentations and can be injected through a wide-bore needle. 

Zoladex (goserelin acetate injectable implant) Prostate cancer AstraZeneca... 

Zoladex Goserelin acetate PLGA Implant Prostate cancer M Shape... 

---